← Eichor
Study identifier: NCT06746519 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia  ·  Sponsor: Chen Suning

PhasePhase 1/Phase 2
Planned participants135
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Suning Chen, Doctor  ·  051265223637  ·  chensuning@sina.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Soochow UniversitySuzhou, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06746519